Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for prevention of COPD exacerbations in smokers
2020-005641-17Phase 3Active
- Sponsor
- Medical University of Białystok
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Atorvastatin arm with Placebo arm (2 arms). Primary endpoint: Exacerbation rate. Started Aug 2021; status: active.
02
Drugs
atorvastatin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2020-005641-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005641-17.